iNewz.in Hindi News

Two Doses Of Covaxin 50 Percent Effective Against Symptomatic Disease According To Lancet Infectious Disease Journal Study

PTI, New Delhi

Published by: Kuldeep Singh
Updated Wed, 24 Nov 2021 05:17 AM IST

Summary

Both doses of Covaxin are up to 50 percent effective in symptomatic patients of corona. This claim has been made in the Real World Assessment of Indian Vaccines published in the Lancet Infectious Disease Journal.

Both doses of Covaxin are up to 50 percent effective in symptomatic patients of corona. This claim has been made in the Real World Assessment of Indian Vaccines published in the Lancet Infectious Disease Journal. However, results from an earlier interim study published in The Lancet showed that two doses of Covaxin, also known as BBV152, were 77.8 percent effective against symptomatic disease. Presents no serious security concerns. But now a study done in India has found it to be up to 50 percent effective.

Study done in AIIMS
The new study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi from April 15 to May 15, who were symptomatic and underwent RT-PCR test for detection of COVID-19. The researchers noted that the study also revealed that the delta variant was the dominant variant in India, accounting for nearly 80 per cent of all confirmed COVID-19 cases.

Manish Soneja, Additional Professor of Medicine, AIIMS, New Delhi, said, “Our study presents a complete picture of how BBV152 (Covaxin) performs. This has to be considered in the context of the growth situation of COVID-19 in India, combined with the potential immunity of the delta variant.

Professor Manish Soneja said in a statement, “Our findings provide evidence that the rapid vaccine rollout program remains the most promising path forward for epidemic control, while public health policies include additional protective measures such as mask-wearing and social distancing.” Should be

Covaxin made by Bharat Biotech
Covaxin has been developed by Hyderabad-based Bharat Biotech in collaboration with National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune. Which is an inactivated complete virus vaccine administered in a two-dose regimen 28 days apart.

In January this year, Covaxin was allowed in India for emergency use for people aged 18 years and above. The World Health Organization added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month. The latest study was conducted during India’s second COVID-19 surge and in healthcare workers who were primarily offered Covaxin.

Expansion

Both doses of Covaxin are up to 50 percent effective in symptomatic patients of corona. This claim has been made in the Real World Assessment of Indian Vaccines published in the Lancet Infectious Disease Journal. However, results from an earlier interim study published in The Lancet showed that two doses of Covaxin, also known as BBV152, were 77.8 percent effective against symptomatic disease. Presents no serious security concerns. But now a study done in India has found it to be up to 50 percent effective.

Study done in AIIMS

The new study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi from April 15 to May 15, who were symptomatic and underwent RT-PCR test for detection of COVID-19. The researchers noted that the study also revealed that the delta variant was the dominant variant in India, accounting for nearly 80 per cent of all confirmed COVID-19 cases.

Manish Soneja, Additional Professor of Medicine, AIIMS, New Delhi, said, “Our study presents a complete picture of how BBV152 (Covaxin) performs. This has to be considered in the context of the growth situation of COVID-19 in India, combined with the potential immunity of the delta variant.

Professor Manish Soneja said in a statement, “Our findings provide evidence that the rapid vaccine rollout program remains the most promising path forward for epidemic control, while public health policies include additional protective measures such as mask-wearing and social distancing.” Should be

Covaxin made by Bharat Biotech

Covaxin has been developed by Hyderabad-based Bharat Biotech in collaboration with National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune. Which is an inactivated complete virus vaccine administered in a two-dose regimen 28 days apart.

In January this year, Covaxin was allowed in India for emergency use for people aged 18 years and above. The World Health Organization added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month. The latest study was conducted during India’s second COVID-19 surge and in healthcare workers who were primarily offered Covaxin.

,

Leave a Reply